Evidence map›Paper›PMID 39987231›Full record

ArticleMolecular psychiatry2025

YY1 mutations disrupt corticogenesis through a cell type specific rewiring of cell-autonomous and non-cell-autonomous transcriptional programs.

Marlene F Pereira, Veronica Finazzi, Ludovico Rizzuti, Davide Aprile, Vittorio Aiello, Luca Mollica, Matteo Riva, Chiara Soriani, Francesco Dossena, Reinald Shyti and 8 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Marlene F Pereira *Department of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.
Veronica Finazzi *Human Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.ORCID 0009-0006-7708-1832
Ludovico RizzutiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.
Davide AprileHuman Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.
Vittorio AielloDepartment of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9, 20122, Milan, Italy.
Luca MollicaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Matteo RivaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.ORCID 0009-0002-7054-1913
Chiara SorianiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.
Francesco DossenaHuman Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.ORCID 0009-0005-4948-4805
Reinald ShytiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.
Davide CastaldiDepartment of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9, 20122, Milan, Italy.
Erika TenderiniDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.
Maria Teresa Carminho-RodriguesDepartment of Genetics, University of Geneva & University Hospitals of Geneva, Geneva, Switzerland.
Julien F BallyService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0970-8844
Bert B A de VriesRadboud University UMC, Nijmegen, The Netherlands.ORCID 0000-0002-0000-2917
Michele GabrieleDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.
Alessandro VitrioloDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-1462-8064
Giuseppe TestaDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy. giuseppe.testa@fht.org.ORCID 0000-0002-9104-0918

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions) 765966EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) Innovative Training Network EpiSyStem
6 · The paper itself

Abstract

Germline mutations of YY1 cause Gabriele-de Vries syndrome (GADEVS), a neurodevelopmental disorder featuring intellectual disability and a wide range of systemic manifestations. To dissect the cellular and molecular mechanisms underlying GADEVS, we combined large-scale imaging, single-cell multiomics and gene regulatory network reconstruction in 2D and 3D patient-derived physiopathologically relevant cell lineages. YY1 haploinsufficiency causes a pervasive alteration of cell type specific transcriptional networks, disrupting corticogenesis at the level of neural progenitors and terminally differentiated neurons, including cytoarchitectural defects reminiscent of GADEVS clinical features. Transcriptional alterations in neurons propagated to neighboring astrocytes through a major non-cell autonomous pro-inflammatory effect that grounds the rationale for modulatory interventions. Together, neurodevelopmental trajectories, synaptic formation and neuronal-astrocyte cross talk emerged as salient domains of YY1 dosage-dependent vulnerability. Mechanistically, cell type resolved reconstruction of gene regulatory networks uncovered the regulatory interplay between YY1, NEUROG2 and ETV5 and its aberrant rewiring in GADEVS. Our findings underscore the reach of advanced in vitro models in capturing developmental antecedents of clinical features and exposing their underlying mechanisms to guide the search for targeted interventions.

Indexed as

YY1 Transcription FactorAstrocytesBasic Helix-Loop-Helix ProteinsCerebral CortexGene Regulatory NetworksHaploinsufficiencyHumansIntellectual DisabilityMaleMutationNeural Stem CellsNeurodevelopmental DisordersNeurogenesisNeuronsTranscription FactorsBasic Helix-Loop-Helix ProteinsTranscription FactorsYY1 protein, humanYY1 Transcription Factor

Identifiers

PMID39987231
PMCPMC12240807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.